NPVI: The Product Vitality Index, Explained

Every few quarters, an executive walks into a room and asks one question: how much of our revenue comes from products we launched recently? NPVI is the answer they want, and it is also the answer that hides the most.

What NPVI is

NPVI, the New Product Vitality Index, is one ratio.

NPVI = (Revenue from products launched in the last N years) / (Total revenue)

If your company did $100M in revenue last year, and $20M of that came from products launched in the last three years, your NPVI is 20%.

That is the whole metric. The simplicity is what gets it onto board decks. The simplicity is also why it gets misused.

3M popularized NPVI in 1988 with a public goal of 30% of revenue from products less than five years old, and the metric has since spread to roughly 62% of large R&D-driven companies that track it in some form (Goldense Group).

Why it shows up in every innovation deck

Four reasons keep NPVI in front of CEOs and CFOs.

Relevance. It directly answers the question every public-company CEO eventually fields: are we still innovating, or are we coasting on the past?

Board-friendly. One number. Trend line over time. No statistical literacy required. CFOs can carry it into an earnings call without a glossary.

The R&D-to-revenue bridge. Companies spend serious money on R&D and product investment. NPVI is the most direct line from that spending to the top line.

Adoption. Roughly 62% of large R&D-driven firms now track NPVI or a close variant. When a metric is widely adopted, comparing yourself to peers gets easier, and peer comparison is half of what board metrics are for.

Benchmarks by industry

Industry context is everything. The same NPVI score can mean "world-class" in one industry and "falling behind" in another.

A few specifics worth keeping in mind. 3M itself ran around 33% a decade ago, slid to 10% in FY2024, and recovered to 13% in FY2025 with a stated 20% target for 2027 (3M FY2024 results). The same company can drift across the "healthy" range over a few years. Kraft Heinz publicly targets around 8% on a 3-year window, which sits comfortably inside the CPG band (Mission Field). Comparing a CPG company to a hardware company on NPVI is comparing apples to forklifts.

Setting up NPVI properly

The metric is only as good as the rules around it. Five setup decisions determine whether your NPVI tells the truth or flatters the deck.

1. Define the window (N years)

Three years, five years, seven? This is the most consequential choice. Short windows (3 years) favor fast-moving categories: software, consumer electronics, fashion. Long windows (5-7 years) suit pharma, industrials, hardware. Pick the window that matches your average product development and adoption cycle, not the one that flatters this quarter.

2. Define what counts as "new"

Three common rules, listed loosest to tightest:

• Brand new SKU or product: clean, defensible, but excludes important reinventions
• Significant variant or refresh: allows for "new" to mean a major upgrade, opens the door to gaming
• Strict launch criteria: new revenue model, new platform, new category, new customer segment

The "significant variant" rule is where most companies quietly inflate. A new color, a new size, a relaunched flavor with the same formula. Pick the strictest defensible definition and document it in the metric appendix. Auditors will thank you. So will the next CFO.

3. Pick the financial metric

Revenue is the default. Gross profit is more useful and almost no one publishes it. Net contribution after marketing is the most honest and the hardest to extract from your finance system. Start with revenue, then add a gross-profit variant as a companion. The gap between the two tells you whether your new products are economically real.

4. Choose the scope

Company-wide, business-unit, geography, channel. Each scope answers a different question. Most teams report a company-wide NPVI to the board and a BU-level NPVI internally. The BU view is where management decisions actually get made.

5. Document the methodology in writing

This is the boring step that saves you twelve months from now when a new CFO asks why the number moved. Write down: window, definition of new, financial metric, scope, treatment of acquisitions, treatment of price changes. Version the document. The definitions are where the real decisions live.

Where NPVI helps

• Forces an honest portfolio conversation. If 80% of revenue comes from products older than 10 years, that is a leadership conversation, not a footnote.
• Trends matter more than levels. A company moving from 8% to 15% is doing something different than one drifting from 22% to 15%.
• Cross-BU comparison inside a company. Same window, same definition, same finance system. Internal NPVI comparisons are some of the cleanest you can run.
• R&D budget defense. When R&D spend gets questioned, NPVI is the cleanest top-line counter-argument finance teams will accept.
• Easy to communicate externally. Investor decks, annual reports, ESG narratives, all benefit from one number that points in one direction.

Where NPVI misleads

Seven blind spots, in roughly the order they show up in practice.

• Lagging indicator. NPVI tells you what happened, not what is coming. By the time NPVI dips, the bets that would have fixed it are years late.
• Punishes patience. Some products take 5-10 years to scale. Aerospace, medical devices, enterprise platforms. NPVI penalizes the companies that play the longest games.
• Gameable. Refresh an existing product, call it new, NPVI goes up. Companies do this. It inflates NPVI without inflating actual innovation.
• Platform-blind. A platform that enables 30 future products generates zero NPVI in the year it ships. Apple Silicon was the most consequential product decision Apple made in a decade and it contributes nothing to NPVI under strict rules.
• Ecosystem-blind. A new product that pulls 10x its own revenue in halo sales gets credit only for itself. Services, accessories, attach revenue all go to other buckets.
• Flattens strategic distinctions. A me-too SKU and a category-defining product both contribute equally. A company can be massively innovative and still score badly on NPVI.
• Industry-context-bound. The same number means different things in pharma and SaaS. Benchmark drift across industries is the most common executive misread of this metric.

A worked example: Apple

Apple is the cleanest demonstration of how NPVI can give you two correct numbers, neither of which is useful.

The strict NPVI. What product lines did Apple launch in the last five years? Vision Pro, redesigned Mac Studio, the Studio Display, Apple Watch Ultra, AirTag. Combined estimated revenue from these new product lines is in the single-digit billions against total revenue of $416B (Bank of America estimates Vision Pro at roughly $3.5B in 2025, up from $1.4B in 2024; Apple does not break out the rest). The math: roughly $4-6B against $416B. Apple's strict NPVI is somewhere between 1% and 1.5%. By that number, Apple stopped innovating.

The loose NPVI. If you count every new SKU, every new chip, every new iPhone model, the number probably crosses 50%. By that number, Apple is hyper-innovative.

Both are correct and neither tells you what to do.

What NPVI cannot see at Apple: the silicon transition that re-architected the entire Mac line, the Services business that has grown roughly fivefold in a decade (from under $20B in FY2015 to over $109B in FY2025) and now drives more than half of Apple's revenue growth (Apple FY2025 10-K, Statista chart), the ecosystem lock-in that makes the iPhone stickier each year. NPVI sees product launches. It does not see the bets that make future product launches possible.

This is the deepest critique of NPVI. The metric is good at measuring what already shipped. It is bad at measuring why the next decade will look the way it does.

Companion metrics that fix NPVI's blind spots

Run NPVI with three companions and most of its blind spots disappear.

Profit Vitality Index. Dan Adams at the AIM Institute makes the case directly: revenue NPVI tells you what shipped, profit NPVI tells you whether the shipping was worth it. Same calculation, gross profit in the numerator and denominator. The gap between revenue NPVI and profit NPVI is where economically thin "innovation" hides (AIM Institute).

Pipeline NPV (forward-looking). Pipeline NPV looks forward where NPVI looks back. Roll up risk-adjusted NPV of products in development, expected launch in the next three to five years. If pipeline NPV is shrinking while NPVI looks healthy, you are coasting.

Portfolio split (innovation type). Mix of incremental, adjacent, and transformational revenue. NPVI counts all three the same way. The split tells you whether you are renewing the core, expanding adjacencies, or making real category bets.

Ecosystem contribution. What share of revenue comes from products launched in the last N years AND from products that pulled new attach revenue into older products? This is where NPVI is most blind, and where the most strategic value usually sits.

Rolling NPVI out in your org

A practical 5-step rollout, in the order that works:

1. Get the definitions done before you compute anything. Window, "new," financial metric, scope, acquisitions, price changes. Write it down. Get finance to sign off.
2. Run a baseline year quietly. Compute the last three years of NPVI internally. Do not socialize the number until the methodology is stable.
3. Pair it with the three companion metrics from the start. Profit Vitality, pipeline NPV, portfolio split. Never publish NPVI alone.
4. Set a target that respects your industry band. A pharma company targeting 40% will fail and learn nothing useful. A CPG company hitting 8% should be applauded, not pushed to 25%.
5. Refresh the methodology every two years. Categories evolve, "new" evolves, your finance system evolves. Lock the methodology and the benchmark will rot in place.

Common watch-outs

• The CFO inheritance problem. New CFO arrives, asks why NPVI moved. If you cannot point at a written methodology, you will spend a quarter relitigating definitions.
• The "refresh as new" creep. Every quarter, someone proposes counting a minor variant as new. Document the bar and enforce it. Once it slips, NPVI loses its meaning.
• Acquisitions. Treat acquired revenue as "new" only if the acquired product launched recently under its own steam. Otherwise you are buying the metric.
• Currency and price effects. Strip price changes and FX out of NPVI. A 5% price increase on legacy products will lower NPVI without anyone innovating less.
• Comparison theater. Resist the temptation to put your NPVI next to a different industry's NPVI on the same slide. It is the most common executive misread of the metric.

Bottom line

NPVI is a thermometer, not a steering wheel. It tells you something real about the temperature of your portfolio, but it does not tell you where to go. McKinsey reached for exactly that analogy in its consumer-goods innovation work, arguing the vitality index can confirm a problem but rarely diagnoses one (McKinsey).

Use it. Define it tightly. Pair it with the companions. Read it in the context of your industry. And when a leader asks "are we still innovating?", let NPVI be the start of the conversation, not the end of it.

Sources and further reading

• Goldense Group, "Return On Innovation and the Vitality Index Are The Most Adopted R&D Product Development Metrics During The Last Decade" — origin of the 1988 3M goal and the 62% adoption statistic.
• 3M, "Reports Fourth-Quarter and Full-Year 2024 Results" — the FY2024 10% NPVI figure and the FY2027 20% target.
• Mission Field, "Setting Top Tier Innovation Goals for CPG Innovation: The Vitality Index" — Kraft Heinz's ~8% target and the CPG band.
• Apple FY2025 10-K (SEC filing) and the Q4 FY2025 press release — total revenue $416B, Services crossing $109B.
• Statista, "Apple Services Revenue" — services growth from under $20B in FY2015 to over $109B in FY2025 (roughly fivefold).
• Six Colors, "Apple's Fiscal 2025 in Charts" — additional context on Apple's revenue mix and Services trajectory.
• Bank of America estimates via AppleInsider coverage — Vision Pro revenue of roughly $1.4B in 2024 and $3.5B in 2025.
• Dan Adams, AIM Institute, "Add a Profit Vitality Index to your Revenue Vitality Index" — the companion-metric argument used in this article.
• McKinsey, "Will innovation finally add up for consumer-goods companies?" — the "thermometer" framing for the vitality index.